Study study type PathologyT1T0Patientssample sizesROB Results

mBC - TNBC - L1 - all population breast cancer - triple negative mBC - Triple negative (TNBC) - 1st Line (L1) mBC - TNBC - L1 - all population

versus Standard of Care (SoC)
veliparib plus paclitaxel plus carboplatin
BrighTNess (velaparib-P-C (arm A) vs paclitaxel - carboplatin (arm B)), 2018
  NCT02032277
RCTmBC - TNBC - L1 - all populationveliparib plus paclitaxel plus carboplatinplacebo plus paclitaxel plus carboplatinPatients: women who had histologically or cytologically confirmed invasive TNBC, clinical stage II-III316 / 160NA
inconclusive
  • inconclusive 12 % increase in events or deaths (EFS) (PE)
  • inconclusive 25 % increase in events or deaths (EFS) (PE)
  • inconclusive 16 % decrease in pCR (PE)
BrighTNess (velaparib-P-C (arm A) vs paclitaxel alone (arm C)), 2018
  NCT02032277
RCTmBC - TNBC - L1 - all populationveliparib plus paclitaxel plus carboplatinplacebo matching veliparib plus placebo matching carboplatin plus paclitaxelPatients: women who had histologically or cytologically confirmed invasive TNBC, clinical stage II-III316 / 158NA
conclusif
  • inconclusive 18 % decrease in deaths (OS) (PE)
  • demonstrated 1.5-fold increase in pCR (PE)
  • suggested 37 % decrease in events or deaths (EFS) (PE)